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A systematic approach to diverse, lead-like
scaffolds from a,a-disubstituted amino acids†
Daniel J. Foley,a Richard G. Doveston,a Ian Churcher,b Adam Nelson*ac and
Stephen P. Marsden*a
A powerful strategy for the efficient lead-oriented synthesis of novel
molecular scaffolds is demonstrated. Twenty two scaffolds were
prepared from just four a-amino acid-derived building blocks and a
toolkit of six connective reactions. Importantly, each individual
scaffold has the ability to specifically target lead-like chemical space.
There is an intrinsic link between themolecular properties of initial
screening compounds and the likelihood of their successful pro-
gression towards drug candidates.1,2 Since both molecular weight
and lipophilicity tend to increase during the lead optimisation
phase,3 controlling the molecular properties of lead molecules is
crucial if the final compounds are to remain in drug-like space.
However, a recent survey concluded that just 2.6% of 4.9 M
commercially-available molecules were lead-like,4 even before com-
pound diversity5 was considered. It has also been shown that
compounds with higher fractions of sp3-hybridised atoms have
lower attrition rates than less saturated compounds,2 and thus may
serve as better leads. Obtaining large numbers of diverse, highly
three-dimensional, lead-like small molecules is thus a major
challenge in maintaining high-quality screening collections. The
concept of lead-oriented synthesis has been proposed4 to frame the
challenge of delivering diverse molecules with specific molecular
properties of direct relevance to the drug discovery and develop-
ment process.4,6,7 Lead-oriented syntheses should, inter alia,4 focus
on the diversity of structures generated, synthetic eﬃciency, toler-
ance to polar functionality, and not be susceptible to ‘LogP drift’,
the phenomenon whereby higher failure rates of more polar
compounds in a given array synthesis leads to an increase in mean
and median logP for final libraries versus that designed. The
significant academic challenge laid down by such demands has
recently begun to prompt the syntheses of specific classes of lead-
like molecules.8
Making diverse compound libraries is not necessarily diﬃcult
per se, but without careful planning comes at the expense of
synthetic eﬃciency and, until recently,8a has lacked a lead-oriented
focus. In order to realise eﬃcient lead-oriented synthesis, our
approach is to exploit small building blocks that contain multiple
chemically-orthogonal functional groups; systematic exploitation of
a minimal toolkit of reactions for the pairwise coupling of the
functional groups present would rapidly deliver diverse scaﬀolds
that, on decoration of the newly formed or residual functional
groups, should target broad regions of lead-like chemical space.
To validate our strategy, we chose readily available9 a-allyl
a-amino acid derivatives 1 as the substrates, the amine func-
tionality of which would then be armed with a functional group
(blue) to yield a trifunctional intermediate 2, tuning the precursor
for cyclisation with either the adjacent ester (green;- 3) or alkene
(red;- 4) (Scheme 1). Variation of the resulting scaﬀold should be
Scheme 1 Overview of themodular synthetic approach. Panel A: attachment
of alternative functional groups (blue) to a-allyl a-amino acid building blocks
1 yields intermediates 2 which may cyclise to yield alternative scaffold topo-
logies 3 or 4. Panel B: structures of the specific building blocks used.
a School of Chemistry, University of Leeds, Leeds, LS2 9JT, UK.
E-mail: s.p.marsden@leeds.ac.uk, a.s.nelson@leeds.ac.uk
bGlaxoSmithKline Medicines Research Centre, Stevenage, SG1 2NY, UK
c Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds,
LS2 9JT, UK
† Electronic supplementary information (ESI) available: Experimental procedures,
compound characterisation data, copies of 1H and 13C NMR spectra, and details of
the virtual library enumeration/analysis. See DOI: 10.1039/c5cc03002a
Received 10th April 2015,
Accepted 11th May 2015
DOI: 10.1039/c5cc03002a
www.rsc.org/chemcomm
ChemComm
COMMUNICATION
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
1 
M
ay
 2
01
5.
 D
ow
nl
oa
de
d 
on
 2
7/
05
/2
01
5 
08
:3
1:
49
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
View Journal
Chem. Commun. This journal is©The Royal Society of Chemistry 2015
possible by exploiting acyclic or cyclic amino acid derivatives (e.g.
1a–d) as substrates; by varying the appended functionality (blue);
and by varying the cyclisation reaction.
Firstly, allylation of commercial N-Boc-protected amino acid
esters furnished the trifunctional building blocks 1.9 Additional
intermediates bearing alternative N-substituents were prepared
to tune the precursors 1 for cyclisation (Scheme 2, Panel A).
Removal of the Boc-protecting group was followed by formation of
acyl ureas 6 (treatment with ethyl isocyanatoformate) or by alkyla-
tion to give protected 1,2-diamines 9, o-bromobenzylamines 12 and
allylamines 15. We then used these substrates to synthesise cyclic
molecular scaﬀolds, by exploiting the use of a toolkit of three broad
reaction types, all targeting medicinally relevant motifs.
1,2-Amino alcohols, 1,2-diamines and their functionalised
derivatives are prevalent inmany bioactivemolecules.10We therefore
explored introduction of these motifs by pairwise coupling of the
p-nucleophilic allyl group with the nucleophilic N-acyl substituents
of 1 and 6 (carbamate11 or urea12 respectively) upon activation with
iodine; subsequent treatment with NaN3 gave cyclic carbamates
5a–5d and the biologically relevant13 ureas 7a–c.
Pairwise coupling of the electrophilic carboxylate ester with
nitrogen-centred nucleophiles led to hydantoins 8a,8c–d (a motif
known for anticonvulsant biological activity, e.g. phenytoin) from
acyl ureas 6 and lactams 10a–b/diketopiperazine 11d from pro-
tected amines 9. Finally, ring closure between the N-substituent
and the C2-allyl group could be facilitated through transition metal
catalysis: Pd-catalysed Heck cyclisations of substrates 12 gave the
azepanes 13a–d and the azocane 14c. Similarly, Ru-catalysed ring-
closing metathesis allowed the synthesis of the indolizidine
alkaloid-like tetrahydropyridines 16a and the congeners 16b–d. In
Scheme 2 Synthesis of diverse lead-like molecular scaffolds. Coloured boxes correspond to different cyclisation reactions, new bonds/groups are
shown in red. Panel A: synthesis of scaffolds from 1a. Panel B: extension to alternative scaffolds using building blocks 1b–d. Standard methods: A: TFA,
CH2Cl2; B: (i) I2, THF–H2O; (ii) NaN3, DMF; C: (EtO2C)NCO, CH2Cl2; D: (i) I2, Li[Al(O
tBu)4], THF, 5 1C; (ii) NaN3, DMF; E: NaOMe, 85 : 15 MeOH–PhMe,
65 1C; F: N-Boc-glycinal, NaBH(OAc)3, CH2Cl2, 4 Å MS; G: (i) TFA, CH2Cl2; (ii) Cs2CO3, DMF, D; H: 2-Br-C6H4CHO, NaBH(OAc)3, CH2Cl2, 4 Å MS; I: 5 mol%
Pd(PPh3)4, Et3N, MeCN, mw, 125 1C; J: allyl bromide, K2CO3, DMF; K: 2.5 mol% Grubbs II, TsOH, PhMe, D; L: EDCI, N-Boc-glycine, Et3N, CH2Cl2.
a See ESI†
for variation from standard methods. bProduct not purified before subsequent reaction. cYield over 2 steps. d92 : 8 mixture with the regioisomeric
azocane. eThe regioisomeric azocane 14c also isolated (31% yield).
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this way we prepared 22 distinct scaffolds from the four building
blocks 1a–d in a total of just 49 synthetic operations‡ using a
toolkit consisting of only six reaction methodologies and one
N-capping event.
To assess the novelty of these scaﬀolds, substructure searches
against the ZINC and CAS databases were performed. A total of
37 variants of the scaﬀolds (with protecting groups removed and
allowing for modifications available through standard functional
group interconversions; see ESI† for full details) were screened
against the ZINC database of 9 039 756 commercially available
compounds. This returned only 28 hits, all of which were derived
from just two of the scaﬀolds (10a/16a). A further analysis of the
Murcko assemblies of all scaﬀolds (with alpha-attachments)
against a random 5% of the ZINC database again only returned
hits (4) against the same two scaﬀolds 10a/16a. Thus, it is clear
that the scaﬀolds display a very high degree of novelty relative to
commercial collections. Finally, the scaﬀolds were also assessed
for skeletal diversity: using an hierarchical approach14,15 it was
found that each scaﬀold comprised a unique molecular framework
at the GNB level.§ Thus, the scaﬀolds are not simple derivatives of
each other, but represent a skeletally diverse collection.
The potential of the scaﬀolds to provide access to lead-like
screening compounds was demonstrated by enumeration of a
virtual library of 1110 compounds from the deprotected scaﬀolds
and 80 typical medicinal chemistry capping groups (see ESI†).
Assessment of the lead-likeness of the virtual library (Fig. 1, Panel
A) showed that 66% of compounds survived filtering by molecular
size (14r heavy atom countr 26; m = 22.8, s = 3.57), lipophilicity
(1o A logPo 3; m = 0.38, s = 1.38) and structural filters (see ESI†).
By comparison, just 23% of theB9 M compounds from the ZINC
database15 survived this filtering process, with most compounds
lying well outside lead-like chemical space (heavy atoms: m = 25.9,
s = 5.4; A logP: m = 1.7, s = 2.9). Remarkably, using the same set of
capping groups, each of the 22 scaﬀolds allowed significant lead-like
chemical space to be targeted. In addition to this in silico study, we
have shown practically that decoration of exemplar scaﬀolds is
possible (ESI†).
The shape diversity of the virtual library was compared with
that of 90 911 randomly-selected compounds from the ZINC
database (Fig. 1, Panel B). For each compound, the two normal-
ised principal moments of inertia values were determined for a
low energy conformation.16 The virtual library was significantly
more three-dimensional (Fsp3: m = 0.57) than the commercially-
available compounds (Fsp3: m = 0.33).
In this study we have shown that careful selection of small,
polyfunctional substrates facilitates an eﬃcient approach to the
synthesis of molecular scaﬀolds that are novel, diverse, and can
specifically target lead-like chemical space. This was achieved
using a toolkit of just six cyclisation methodologies, leading to
22 scaﬀolds in only 49 synthetic operations. In particular, the
eﬃcient and diverse coverage of 3D space from such a small set
of reagents is notable. This general approach should be applicable
to many classes of polyfunctional substrate, enabling the more
eﬃcient exploration of lead-like chemical space.
We thank EPSRC (EP/J00894X) and GSK for funding.
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